Rapid and Accurate Diagnosis of the Respiratory Disease Pertussis on a Point-of-Care Biochip.

EClinicalMedicine

Department of Chemistry and Biochemistry, Biomedical Engineering, Border Biomedical Research Center, Environmental Science and Engineering, University of Texas at El Paso, 500 West University Ave, El Paso, TX 79968, USA.

Published: February 2019

AI Article Synopsis

  • A new low-cost, instrument-free diagnostic method has been developed for rapid detection of pertussis, a highly contagious respiratory disease, suitable for use in resource-limited areas.
  • The diagnostic tool integrates a paper/polymer hybrid microfluidic biochip with a loop-mediated isothermal amplification (LAMP) method, allowing results to be read visually within 45 minutes with high accuracy (100% sensitivity, 96% specificity) compared to traditional PCR tests.
  • This innovative approach enables direct testing of clinical samples without complex processing, making it a promising option for point-of-care diagnosis in schools, clinics, and other settings, especially in developing countries.

Article Abstract

Background: Pertussis is a highly contagious respiratory disease caused by the bacterium (). The infection is difficult to diagnose especially in underserved or resource-limited areas. We developed a low-cost and instrument-free diagnostic method for rapid and accurate detection of on a point-of-care (POC) testing device.

Methods: We developed a paper/polymer hybrid microfluidic biochip integrated with loop-mediated isothermal amplification (LAMP) method for the rapid and accurate detection of . This microfluidic approach was validated by testing 100 de-identified remnant clinical nasopharyngeal swabs and aspirates, which were confirmed to be either positive or negative for by a validated real-time PCR assay at the Children's Hospital Los Angeles.

Findings: The instrument-free detection results could be successfully read by the naked eye within 45 min with a limit of detection (LOD) of 5 DNA copies per well. Our optimized bacterial lysis protocol allowed the direct testing of clinical samples without any complicated sample processing/preparation (i.e. DNA extraction) or the use of any equipment (e.g. centrifuges). The validation of the microfluidic approach was accomplished by testing 100 clinical samples. High sensitivity (100%) and specificity (96%) with respect to real-time PCR were achieved.

Interpretation: This microfluidic biochip shows great potential for point-of-care disease diagnosis in various venues including schools and physician's offices, especially in low-resource settings in developing nations.

Funding: NIH/NIAID under award number R21AI107415, NIH RCMI Pilot Grant, the Philadelphia Foundation, the Medical Center of the Americas Foundation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469871PMC
http://dx.doi.org/10.1016/j.eclinm.2019.02.008DOI Listing

Publication Analysis

Top Keywords

rapid accurate
12
respiratory disease
8
method rapid
8
accurate detection
8
microfluidic biochip
8
microfluidic approach
8
testing 100
8
real-time pcr
8
clinical samples
8
accurate diagnosis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!